Bethlehem, PA, June 1, 2018 – Ophidion, Inc., a biotechnology company advancing innovative gene silencing therapeutics for the treatment of brain diseases, has hired Yacoub Habib, Ph.D./MBA as its Chief Executive Officer.
Bethlehem, PA, May 15th, 2018 – Ophidion, Inc., a biotechnology company advancing innovative gene silencing therapeutics for the treatment of brain diseases, announced today that it is a recipient of the latest investment cycle of the Ben Franklin Technology Partners of Northeastern Pennsylvania (BFTP/NEP) network regional economic development investment program. The BFTP/NEP investment was for $100,000 to support a definitive pre-clinical study to optimize delivery of central nervous system therapeutics to targeted sites in the brain. Ophidion is leveraging its proprietary blood-brain barrier transport technology to advance a systemically delivered gene-silencing siRNA product for the treatment of Huntington’s disease, a fatal neurodegenerative disease with no current cure. The Ben Franklin Technology Partners’ Board of Directors made investments totaling $695,000 in this cycle in support of regional early-stage companies. These investments are provided in the form of loans with warrants. BFTP/NEP’s goal is to help lead northeastern Pennsylvania to a better economic future by building partnerships that develop and apply technology for competitive advantage.